Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-02-18

FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved a supplemental application for Sandoz Inc.'s carbidopa/levodopa/entacapone product. It is used to treat Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carbidopa/levodopa/entacapone (carbidopa; levodopa; entacapone)

Snippet

SUPPL AP for CARBIDOPA, LEVODOPA, AND ENTACAPONE (CARBIDOPA, LEVODOPA, AND ENTACAPONE)